TCS 359, a 2-acylaminothiophene-3-carboxamide, serves as a potent and selective FLT3 inhibitor with an IC50 of 42 nM. It also suppresses MV4-11 cell proliferation with an IC50 of 340 nM [1].
TCS 359 细胞实验
Cell Line
Concentration
Treated Time
Description
References
ImMKCLs
3.3 µM
10 days
To evaluate the effect of TCS 359 on iPSC-derived MK maturation and PLP production. Results showed that TCS 359 significantly increased PLP yield.
Blood Adv. 2018 Sep 11;2(17):2262-2272.
3LL tumor cells
25, 50, 100 mg/ml
24, 48, 72 hours
TCS inhibited the proliferation of 3LL cells in a time- and dose-dependent manner and induced apoptosis after 48 hours of treatment.
Cell Mol Immunol. 2011 Jul;8(4):359-67.
ImMKCLs
3.3 µM
7 days
To evaluate the effect of TCS 359 on imMKCL maturation and platelet-like particle (PLP) production. Results showed that TCS 359 significantly increased PLP yield.
Blood Adv. 2018 Sep 11;2(17):2262-2272.
TCS 359 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice and nude mice
Lewis lung cancer model
Subcutaneous injection
0.4 mg/kg
Once every other day for a total of five times
TCS more significantly inhibited tumor growth and prolonged survival in immunocompetent mice than in nude mice, indicating that the host immune system was involved in tumor eradication.
Cell Mol Immunol. 2011 Jul;8(4):359-67.
C57BL/6JRj mice
Anti-GPIbα antibody-induced thrombocytopenia model
Intraperitoneal injection
100 mg/kg
From day 0 to day 6
To evaluate the effect of TCS 359 on platelet recovery. Results showed that TCS 359 significantly promoted platelet recovery.
搜索
